Free Newsletter
Pfizer taps litigator as new GC
Say hello to Pfizer's new general counsel, Amy Schulman (photo), a top litigator who's served as lead attorney on the company's Celebrex and Bextra cases. A partner at DLA Piper, Schulman specializes in defending companies against big product liability lawsuits. She's a top producer for that firm who earned $5.75 million last year. Schulman, 47, replaces Allen Waxman, who left Pfizer in March for personal reasons; she'll report directly to CEO Jeff Kindler, who's also a lawyer. “Her knowledge of the legal, business and regulatory challenges facing the pharmaceutical industry and her experience tackling large, complex cases make her uniquely qualified to lead Pfizer’s legal team," Kindler said in a statement.
- find Pfizer's release
- see the Wall Street Journal story
- check out the WSJ Law Blog's item
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





